Core Viewpoint - The commercial dispute over the exclusive distribution rights of the "AestheFill" product between Jiangsu Wuzhong and Regen Biotech has escalated, leading to significant implications for both companies and the medical aesthetics industry as a whole [2][3][4]. Group 1: Company Actions and Responses - Jiangsu Wuzhong announced that it would seek arbitration to confirm the validity of the exclusive distribution agreement and is claiming damages of 1.6 billion yuan, covering development costs and potential profits [8]. - Following the receipt of a termination letter from Regen, Jiangsu Wuzhong initiated a legal response, asserting that there was no transfer of exclusive rights and that the termination was unjustified [6][11]. - Aimeike, which has taken operational control of Regen, has been accused by Jiangsu Wuzhong of manipulating the situation to undermine its distribution rights [17]. Group 2: Financial Impact - Jiangsu Wuzhong's stock price has dropped over 40% since receiving the termination notice, with its market capitalization falling to 704 million yuan [3]. - The "AestheFill" product has been a significant revenue driver for Jiangsu Wuzhong, contributing 3.26 billion yuan in sales in its first year and 1.13 billion yuan in the first quarter of 2025 [9]. - The company reported a net profit of 70.48 million yuan in 2024, a 197.97% increase, largely attributed to the success of "AestheFill" [9]. Group 3: Industry Implications - The dispute has created uncertainty in the medical aesthetics industry, potentially causing anxiety among distributors and affecting market dynamics [3][12]. - The conflict highlights deeper issues within the industry regarding the balance of power between brand owners and distributors, with the latter often feeling insecure in their roles [17]. - Aimeike is also facing its own growth challenges, with a significant slowdown in revenue growth, indicating that the competitive landscape is becoming increasingly difficult for all players involved [13].

Core Viewpoint - A commercial dispute over the代理权 of "童颜针" (AestheFill) between *ST苏吴 and爱美客 has escalated, with *ST苏吴 seeking 1.6 billion yuan in arbitration against爱美客's subsidiary, Regen Biotech, for breach of contract [1][5][9]. Group 1: Background of the Dispute - The dispute originated on July 18, when爱美客 sent a termination letter to达透公司, revoking its exclusive distribution rights for AestheFill in mainland China [1][5]. -达透公司 had previously secured exclusive sales rights for AestheFill in China through a tripartite agreement signed in August 2022, valid until August 2032 [2][5]. Group 2: Financial Implications - AestheFill has significantly contributed to *ST苏吴's financial performance, generating 3.26 billion yuan in sales revenue in 2024, accounting for 20.42% of the company's total revenue [10]. - The medical aesthetics sector, driven by AestheFill, reported a staggering revenue increase of 4225.64% year-on-year, reaching 3.03 billion yuan in 2024 [10]. Group 3: Market Dynamics - The "童颜针" market is rapidly expanding, with its size growing from 6 billion yuan in 2023 to over 30 billion yuan in 2024, indicating a strong growth trajectory [12]. - The global market for "童颜针" is projected to reach approximately 1.54 billion USD (about 11.04 billion yuan) by 2025, further highlighting its potential as a lucrative segment [12]. Group 4: Competitive Landscape - The dispute reflects the competitive nature of the medical aesthetics market, with both companies vying for control over a high-margin product that has shown remarkable profitability [14]. - As the number of approved "童颜针" products increases, industry experts predict a potential decline in profit margins due to heightened competition [14].

Core Viewpoint - Jiangsu Wuzhong's subsidiary, Datou Medical, has received a termination letter from Regen Biotech, which demands the cancellation of Datou Medical's exclusive distribution rights for the AestheFill product in mainland China, raising concerns about the company's future in the medical aesthetics sector amid ongoing financial scandals [1][2]. Group 1: Company Response and Legal Actions - Jiangsu Wuzhong has initiated a response plan upon receiving the termination letter and is in communication with Regen, indicating that legal action may be taken if necessary to protect its rights [2]. - Regen's reasons for termination include allegations that Datou Medical transferred exclusive distribution rights to its parent company, and concerns over Jiangsu Wuzhong's legal violations affecting the product's reputation [2]. Group 2: Market Impact and Financial Performance - The change in the registration agent for AestheFill from Datou Medical to Lizhen (Beijing) Biotechnology Co., owned by Regen, introduces uncertainty regarding the previously secure exclusive distribution agreement [4]. - In 2024, Jiangsu Wuzhong reported a revenue of 1.599 billion yuan, a decline of 28.64% year-on-year, with the medical aesthetics segment generating 330 million yuan, a significant increase of over 40 times [4]. - If the exclusive distribution agreement is ultimately terminated, Datou Medical would lose its rights to sell AestheFill, leading to a substantial decrease in revenue and profit for the medical aesthetics segment in the latter half of the year [5].

Core Viewpoint - Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. has been found to have multiple violations of information disclosure from 2018 to 2023, including concealing changes in actual control and inflating revenue and profits for four consecutive years, leading to a risk of forced delisting [1][2]. Group 1: Information Disclosure Violations - The company concealed the change of actual controller from Suzhou Wuzhong Investment Holdings Co., Ltd. to Qian Qunshan, misrepresenting Qian Qunying as the actual controller in annual reports from 2018 to 2023, resulting in long-term false records [2]. - From 2020 to 2023, the company inflated revenue by a total of 1.77 billion yuan through fictitious trade transactions with three subsidiaries and related parties, with annual inflated revenue detailed as follows: - 2020: 495 million yuan (26.46% of revenue) [2] - 2021: 469 million yuan (26.39% of revenue) [2] - 2022: 431 million yuan (21.26% of revenue) [2] - 2023: 377 million yuan (16.82% of revenue) [2]. Group 2: Financial Mismanagement - The company used fictitious trade procurement payments to transfer funds to related parties, with the balance of funds occupied increasing from 127 million yuan at the end of 2020 to 1.693 billion yuan by the end of 2023, representing a rise in net asset proportion from 6.88% to 96.09%, nearly depleting the company's assets [3]. Group 3: Operational Challenges and Market Reaction - Despite a temporary recovery in the medical beauty sector with a 4225.65% year-on-year revenue increase from the Korean product "AestheFill," the company forecasted a net loss of 40 to 60 million yuan for the first half of 2025, primarily due to increased impairment provisions for trade receivables [4]. - The company faces severe delisting risks, as the final penalties for financial fraud could trigger mandatory delisting clauses. The stock price dropped to 2.19 yuan per share on July 14, 2025, reflecting a market value loss of over 75% within the year [4]. Group 4: Industry Implications - The Jiangsu Wuzhong case highlights systemic governance failures in some listed companies, including concealment of actual controllers, financial fraud, and fund misappropriation, forming a chain of violations [5]. - This case serves as a warning to the market regarding the importance of truthful information disclosure as a cornerstone for the healthy operation of capital markets, indicating that any actions challenging this principle will ultimately incur consequences [5].

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company is acquiring 85% of REGEN Biotech for $190 million, enhancing its position in the regenerative medical aesthetics sector and facilitating international expansion [6] - REGEN Biotech is a leading South Korean company in medical aesthetics, known for its innovative products like AestheFill, which has a strong market presence in 34 countries [6] - The acquisition is expected to strengthen the company's market leadership in high-end regenerative medical aesthetics and optimize costs through synergies in R&D and supply chain management [6] - The company has a robust pipeline of products, including a recently approved medical-grade hyaluronic acid gel and various injectables, which supports its sustainable growth [6] Financial Summary - The company's total revenue is projected to grow from 2,869 million RMB in 2023 to 3,987 million RMB in 2026, reflecting a compound annual growth rate (CAGR) of approximately 12.35% [1][7] - Net profit attributable to the parent company is expected to increase from 2,084 million RMB in 2024 to 2,656 million RMB in 2026, with a CAGR of about 12.97% [1][7] - The earnings per share (EPS) is forecasted to rise from 6.14 RMB in 2024 to 8.78 RMB in 2026, indicating a positive trend in profitability [1][7] - The price-to-earnings (P/E) ratio is projected to decrease from 29 times in 2024 to 22.81 times in 2026, suggesting an attractive valuation as earnings grow [1][7]

证券研究报告·公司点评报告·医疗美容 执业证书：S0600520090006 wujc@dwzq.com.cn 爱美客（300896） 收购韩国 REGEN，再生医美&国际化布局再 突破 买入（维持） | [Table_EPS] 盈利预测与估值 | 2022A | 2023A | 2024E | 2025E | 2026E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 1939 | 2869 | 3164 | 3549 | 3987 | | 同比（%） | 33.91 | 47.99 | 10.26 | 12.18 | 12.35 | | 归母净利润（百万元） | 1264 | 1858 | 2084 | 2351 | 2656 | | 同比（%） | 31.90 | 47.08 | 12.12 | 12.83 | 12.97 | | EPS-最新摊薄（元/股） | 4.18 | 6.14 | 6.89 | 7.77 | 8.78 | | P/E（现价&最新摊薄） | 47.95 | 32.60 | 29.08 | 25.77 | 22.81 | ...